Ionis Pharmaceuticals has been granted a patent for compounds, methods, and pharmaceutical compositions aimed at reducing LRRK2 RNA and protein levels to potentially ameliorate symptoms of neurodegenerative diseases like Parkinson’s. The patent includes a modified oligonucleotide with a specific chemical structure. GlobalData’s report on Ionis Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Ionis Pharmaceuticals Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Ionis Pharmaceuticals, Nucleic acid active pharmaceutical ingredient was a key innovation area identified from patents. Ionis Pharmaceuticals's grant share as of February 2024 was 39%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11873495B2) discloses a series of claims related to modified oligonucleotides, oligomeric compounds, pharmaceutical compositions, and methods for treating Parkinson's disease. The patent covers modified oligonucleotides with specific chemical structures, including those in sodium or potassium salt form, and populations of these oligonucleotides with stereorandom phosphorothioate internucleoside linkages. Additionally, the patent includes pharmaceutical compositions containing these modified oligonucleotides and suitable carriers like phosphate-buffered saline or artificial cerebrospinal fluid.

Furthermore, the patent outlines methods for administering the pharmaceutical compositions to subjects for treating Parkinson's disease, reducing the expression of LRRK2 in cells, and alleviating symptoms associated with the disease. The methods involve administering therapeutically effective amounts of the pharmaceutical compositions to human subjects, resulting in the amelioration of symptoms such as ataxia, neuropathy, and aggregate formation. Overall, the patent provides a comprehensive framework for utilizing modified oligonucleotides and oligomeric compounds in pharmaceutical compositions to address Parkinson's disease and related conditions, offering potential avenues for therapeutic intervention and disease management.

To know more about GlobalData’s detailed insights on Ionis Pharmaceuticals, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies